Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMN20 KRd vs Rd in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
2024-513396-41-00Phase 3Authorised
- Sponsor
- European Myeloma Network
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network. Primary endpoints: Minimal residual disease (MRD) negativity rate at 2 years and Progression-free survival (PFS). Planned start Aug 2024; status: authorised.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-513396-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513396-41-00.